News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

NuggMD Celebrates Launching Services in 23rd State, Washington

NuggMD

NuggMD, the nation's leading medical marijuana telemedicine platform, has launched its service in Washington state for just $139. Since its founding in 2015, NuggMD has connected over 1,000,000 patients to their medical marijuana physicians via its state-of-the-art telehealth platform. "Telehealth has never been more important for patients who are increasingly feeling the pinch of inflation, especially on the West Coast," said Alex Milligan, NuggMD co-founder and CMO. "We're excited to offer our platform to physicians who wish to provide follow-up care to their patients in Washington state, where appropriate." Washington's registered patient population has fallen to nearly half of its peak of over 20,000 registered patients in 2017, with only 6,315 cards issued so far in 2023. Registration with the state is voluntary, but only registered patients are exempt from cannabis retail taxes. "Sure, there are fewer patients now," said Collin Mann, CEO and NuggMD co-founder. "But Washington's medical program is still very important for both registered and unregistered patients. We hope we can help keep that program alive by helping patients more easily access their physicians." NuggMD's platform is available from 8 am to 10 pm seven days a week. No appointment is needed, and patients who don't qualify for their state's medical cannabis program won't be charged for their evaluation. About NuggMD NuggMD is the nation's largest medical marijuana technology platform, serving patients in California, Connecticut, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com/Washington. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

August 10, 2023 05:31 PM Eastern Daylight Time

Article thumbnail News Release

Xeris Biopharma CEO unveils record quarterly revenue, underpinned by unique business model

Xeris Biopharma Holdings

Xeris Biopharma chairman and CEO Paul Edick joined Proactive's Stephen Gunnion with details of the company's second-quarter performance, which saw record revenue driven by the success of their products, including Gvoke, Keveyis, and Recorlev. For the quarter, which ended on June 30, 2023, the company achieved sales of $38 million, up 50% year-over-year and 14% sequentially. Edick noted that Xeris' unique business model includes three pillars: a thriving commercial business, technology for in-house product development, and partnerships to enhance others' drugs. This diversified approach provides the company with strategic flexibility and options for growth. He also expressed confidence in achieving cash flow breakeven by the fourth quarter and emphasized the company's sustainability without the need for additional public equity sales. Regarding the pipeline program for Xerisol levothyroxine, Edick said Xeris is enrolling in the phase two study. The data collected will shape the phase three trial and regulatory negotiations with the US Food and Drug Administration (FDA). Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

August 10, 2023 11:59 AM Eastern Daylight Time

Video
Article thumbnail News Release

Premium Amanita Muscaria Mushroom Gummies Launched by Exhale Wellness

Blue Ribbon Media

Exhale Wellness, a premiere-rated, all-natural hemp brand, becomes the newest addition to the thriving US psychedelics market with its proud range of mystical mushroom gummies. These spellbinding Amanita Muscaria Mushroom Gummies redefine the landscape for psychoactive gummies with 500mg of pure potency, creating a new benchmark for individuals seeking an escape to their happy place. Crafted using pure Amanita mushrooms without any additives or artificial flavoring, these gummies embody a potent, mystical experience with cruelty-free lab certification testifying to its safety. If you're a gummy connoisseur looking to try trend-breaking new launches, this is your sign to get to know Amanita Muscaria Mushroom gummies well. Understanding The Mystical Amanita Gummies & Its Effects Amanita Muscaria Mushrooms are the easiest to recognize. If you've ever encountered soft, white mushrooms with red polka-dotted tops, know these mushrooms can take you on a mind-expanding, marvelous journey. This mushroom's blend of psychoactive alkaloids is particularly responsible for the mystical experience. Among these, the two alkaloid blends that stand out for their prominent psychoactive personalities are muscarine & ibotenic acid. What makes these psychoactive mushrooms different than other psychedelics is their interaction with various receptors, encouraging mild hallucinogenic properties when taken in a high quantity. Unlocking the wonders with Exhale Wellness Amanita Mushroom Gummies If you're looking for a calming, elevating escape in the form of a wholesome treat, the Amanita mushroom gummies could be your go-to munchie destination. These gummies are crafted using all-natural ingredients along with 5mg of Muscimol and 500mg of Amanita muscaria mushroom fruiting body extract. Amanita mushrooms are less powerful than psilocybin, better known as 'magic' mushrooms, and won't cause a steep feeling of intoxication if used responsibly. However, the effects majorly depend on the quantity and compatibility of the user. For new users, 1/2 a gummy would be the best way to start their mushroom gummy journey. If the craving for a better, more elevated experience persists, users can use the other half of the gummy after 2-3 hours to continue their mystical adventure. Where Do Amanita Mushroom Gummies Stand Legally? Amanita Muscaria Mushroom gummies lack the crude potency 'magic' mushrooms or psilocybin contains, and hence, do not fall under the Controlled Substances list. In the US, Louisiana is currently the only state that has imposed limitations on the distribution and sales of Amanita extract and related products. Safety and Thrills Rolled Into One With Exhale Wellness Amanita Mushroom Gummies The market for psychoactive on-the-go treats is ballooning with each passing day, and mushroom gummies are at the top of the trend list, which means newer variations and more refined experiences are on the horizon. New launches like Exhale Wellness' Amanita Muscaria Mushroom gummies are further propelling the expansion and popularity of these fun-sized treats. However, stringent protocols for quality and safety testing are one of the driving factors that distinguish prominent brands like these from others. About Exhale Wellness Exhale Wellness is an all-natural hemp brand highly regarded for its premium-quality hemp. Sustainably sourced from the finest farms in Colorado, Exhale Wellness is known for its extensive line of Delta-8, Delta-9, Delta-10, THC, HHC, and CBD products, with their newest introduction being Amanita Muscaria Mushroom gummies. All products sourced, manufactured, and advertised are USA-made and safety certified through stringent third-party lab tests to ensure the purity and potency of all products. Contact Details Exhale Wellness Support at Exhale Wellness +1 323-448-3810 support@exhalewell.com Company Website https://www.exhalewell.com/

August 10, 2023 07:14 AM Eastern Daylight Time

Article thumbnail News Release

Delivra Health Brands expands Dream Water to Las Vegas resorts

Delivra Health Brands Inc.

Delivra Health Brands Inc president and CEO Gord Davey joins Proactive's Stephen Gunnion with details of a customer merchandising agreement its Dream Water subsidiary has entered into with two Las Vegas resorts, Treasure Island and Circus Circus, for its Dream Water products. Davey emphasized that the collaboration allows Delivra to place its Dream Water products in kiosks across both resorts, enhancing sales in the US market. It also fits with the company's strategic decision to focus on the travel, hotel/resort and entertainment sectors due to the demand for quality sleep solutions during travel. Apart from product placement, Delivra will implement comprehensive marketing initiatives, leveraging social media and peak periods at the resorts to promote their offerings. Delivra's portfolio includes various Dream Water products, such as sleep shots, immunity, beauty, and sleep gummies, which will be accessible not only in airports across North America but also in Hilton Hotels and now, in Las Vegas. Davey noted that the collaboration with Treasure Island and Circus Circus is anticipated to lead to new customer acquisition. Contact Details Proactive Studio +1 604-688-8158 na-editorial@proactiveinvestors.com

August 09, 2023 02:53 PM Eastern Daylight Time

Video
Article thumbnail News Release

Roquefort Therapeutics making headway with siRNA

Roquefort Therapeutics PLC

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) chief executive Ajan Reginald speaks to Thomas Warner from Proactive after announcing the successful development of new small interfering RNA (siRNA) sequences. Reginald says that siRNA holds immense potential as a cancer treatment, explaining that SiRNA binds to and blocks specific RNA, stopping the production of cancer-fueling substances and ultimately killing cancer cells. He suggests that the technology has been gaining traction since it received the Nobel Prize in 2006, and that Big Pharma is now actively seeking partnerships in the siRNA field. Reginald goes on to say that for Roquefort Therapeutics, the significance of their recent developments lies in their early innovation and focus on STAT6, a key target in their research. The company acquired R&D company Oncogeni last year before STAT6 gained widespread recognition, giving them what he considers a competitive edge in intellectual property and development. He goes on to give a brief overview of the projects Roquefort is currently focused on, concluding by saying that "we're always trying to find new targets... if we can be first to find a new target, that's when shareholders will see very large deals." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

August 09, 2023 07:48 AM Eastern Daylight Time

Video
Article thumbnail News Release

Navis Clinical Laboratories Joins Nashville Area Health Services Community With Grand Opening of New Headquarters

Navis Clinical Laboratories

Navis Clinical Laboratories ( navisclinical.com ), a leading provider of laboratory services that is making groundbreaking strides in health care solutions for substance use disorder and other disease states, celebrated its official grand opening with a ribbon cutting ceremony at its new corporate headquarters located in the Greater Nashville area city of Franklin, Tenn. Focused on innovative, cutting-edge research and development, Navis provides laboratory drug testing solutions and molecular and clinical blood testing for healthcare providers to aid in the diagnosis, treatment, management and prevention of substance use disorder, mental health conditions, chronic pain, and common comorbid acute and chronic diseases, including HIV/AIDS, hepatitis, sexually transmitted infections (STIs), urinary tract infections (UTIs), respiratory infections and antibiotic resistant infections. President and CEO Richard Stripp, Ph.D., who was joined by Navis leadership, employees, friends and family, shared his excitement about Navis’ future. “We’re delighted to be in Nashville, the health services capital of the U.S., and to have the opportunity to bring business and jobs to the area. We have a very aggressive growth strategy, and this is just the beginning for us. We have a national footprint serving clients nationwide, and this move will help facilitate our evolution into a one-stop shop for our clients and allow us to deliver services to patients who really need our help.” Lori Odom, Senior Vice President of Economic Development, Nashville Area Chamber of Commerce, opened the ceremony with a warm welcome to Navis, which joins the area’s robust and diverse health care community of more than 500 health care companies, making it the largest industry in the region. “Nashville is known as Music City, but it is also Healthcare City. Our mission is to create economic prosperity by facilitating leadership and partnership with companies, and Navis is a great example of what that can accomplish,” said Odom. “At Navis, we understand that behind everything we do is a human being whose life is directly impacted by the services we provide,” said Dr. Stripp. “Many patients we serve have complex health conditions. Navigating the healthcare system to find care that treats the whole patient rather than just a single illness is often a challenge. We advocate for those patients by developing solutions that empower healthcare providers to provide exceptional care, improve outcomes and save lives.” Navis launched in February of this year and currently owns three state-of-the-art laboratories located in New York, Washington and Massachusetts, allowing it to provide services nationally to healthcare practices. Dr. Stripp originally founded the New York laboratory location as American Forensic Toxicology Services. About Navis Clinical Laboratories Navis Clinical Laboratories ( navisclinical.com ) believes in advocating for those who can’t advocate for themselves, helping them navigate through challenging times. Focused on innovative, cutting-edge research and development to aid in the diagnosis, treatment, management and prevention of disease, Navis provides toxicology, clinical blood and molecular testing for healthcare providers to help reduce suffering and save the lives of people with substance use disorder, mental health conditions, chronic pain and other acute and chronic diseases. Contact Details Kim Kudasik kkudasik@navisclinical.com

August 08, 2023 06:00 AM Central Daylight Time

Image
Article thumbnail News Release

Therma Bright CEO says permanent insurance codes for Venowave could be a game changer

Therma Bright Inc

Therma Bright Inc CEO Rob Fia discusses the imminent decision on permanent codes for Venowave, its compact, lightweight deep vein thrombosis (DVT) prevention device, with Proactive's Stephen Gunnion. Fia said the importance of securing these codes from the Centers for Medicare and Medicaid Services (CMS) lies in easier reimbursement processes, streamlining billing, and facilitating distribution. Venowave is a groundbreaking compression device that actively moves blood from the calf to the heart, FDA-approved for preventing blood clots and addressing issues like deep vein thrombosis, chronic venous insufficiency, and varicose veins. Unlike pneumatic devices in the market, Venowave employs waveform technology, setting it apart. Fia highlighted the potential market size, estimated at over a billion dollars, and the significant advantage of holding the first permanent code for a compression device. The CEO also elaborated on the expanding US distribution network, including partnerships with a Medicare Advantage healthcare provider and Texas-based doctors' groups. These partnerships offer direct engagement with payers, facilitating billing and reimbursement. Moreover, Therma Bright is also finalizing agreements with a distributor in Connecticut. The anticipated outcome of securing permanent codes for Venowave could revolutionize the industry, simplifying processes and enhancing market reach, Fia said. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

August 07, 2023 01:54 PM Eastern Daylight Time

Video
Article thumbnail News Release

Avricore Health's HealthTab expands globally with UK feasibility study

Avricore Health

Avricore Health CEO Hector Bremner tells Proactive's Stephen Gunnion that HealthTab has been selected for a UK-based feasibility study, marking an important international expansion. Avricore Health has achieved success in Canada with HealthTab, the company's leading pharmacy-based platform for testing and health data management. Now, in partnership with Barts Hart Centre and HEART UK, the platform will be used to support NHS England's efforts to enhance community pharmacy-driven care for cardiovascular disease. The success of the NHS's Health Check program, which conducted over a million opportunistic blood pressure checks, revealed the need for advanced screening methods. Bremner emphasized the increasing role of community pharmacies in global healthcare systems, offering on-demand care beyond emergency rooms. The feasibility study will initially focus on five locations in London, with plans to rapidly scale up to 50 and beyond. Avricore Health envisions HealthTab as a global solution, with consistent demand across markets, and the UK's supportive pharmacy infrastructure and population size make it an ideal starting point. Bremner expressed optimism about HealthTab's potential to revolutionize healthcare delivery internationally. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

August 07, 2023 01:37 PM Eastern Daylight Time

Video
Article thumbnail News Release

Immunic CEO says Q2 results "couldn't be better"

Immunic Inc

Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive following the release of the Munich-based biotechnology company's second-quarter financial results and a corporate update. Dr. Vitt says that the performance of the business during Q2 "couldn't have been better", highlighting what he calls "scientifically a very good quarter and uneventful on the more general financial side." He goes on to give more detail about the progress achieved with Immunic's prospective multiple sclerosis (MS) and celiac disease treatments during the quarter, noting the preclinical data for its most advanced molecule IMU-838 that was published in the Journal of Medicinal Chemistry and positive results From Phase 1b Clinical Trial of IMU-856 in celiac disease. Looking to the future, Dr. Vitt expects more trial data to be released in the fall of this year, and reiterates that the company is fully funded into Q4 of 2024. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

August 07, 2023 09:50 AM Eastern Daylight Time

Video
1 ... 5253545556 ... 207